Japan’s Shionogi & Co. Ltd. believes its COVID-19 pill will easily garner $2 billion in annual sales if it secures U.S. approval, which the company expects to receive in late 2024, its chief executive said.
Pfizer notched another score in the race for an RSV vaccine Tuesday, as it announced the FDA has accepted the Biologics License Application for its maternal RSV vaccine and granted the candidate priority review.
Akebia Therapeutics announced another delay Tuesday in a series of setbacks for vadadustat, being developed to treat anemia linked to chronic kidney disease (CKD).
The U.S. health department proposed on Tuesday three new pilot projects aimed at lowering prescription drug prices for people enrolled in government health insurance plans, including offering some essential generic drugs for $2 a month.
After nearly three years, the COVID-19 research collaboration between Vir Biotechnology and GSK has largely come to an end, as Vir announced Monday it would be going it alone or with other partners in this space.
The U.S. Food and Drug Administration (FDA) has declined to review Soligenix Inc.’s application seeking approval of its cancer treatment, the drug developer said on Tuesday, sending its shares down more than 30% in early trading.
Dozens of U.S. state attorneys general on Friday weighed in on a lawsuit seeking a court order blocking access nationwide to a drug used in medication abortion, with Republicans in support of the lawsuit and Democrats warning of “devastating consequences” if it succeeds.
Bristol Myers Squibb and 2seventy bio published positive results Friday from a pivotal trial of their B-cell maturation antigen–directed (BCMA) CAR T-cell therapy in multiple myeloma patients who had received two to four prior lines of therapy.
The U.S. government has agreed to buy 1.5 million more doses of Novavax Inc. COVID-19 vaccine, the company said on Monday, adding that the modified agreement includes funds for development of an updated vaccine by fall this year.
Blueprint Medicines Corp. said on Friday the U.S. drug regulator had put on partial hold an early-stage trial testing its experimental cancer drug due to safety concerns, sending its shares down nearly 6%.